Literature DB >> 6105967

Evidence for the alpha 2 nature of the alpha-adrenergic receptor inhibiting lipolysis in human fat cells.

M Lafontan, M Berlan.   

Abstract

Theophylline-stimulated human subcutaneous adipocytes were incubatged in vitro in the presence of selected alpha-adrenergic agents in order to characterize the alpha-adrenoceptor of human fat cells. Inhibition of theophylline-induced lipolysis occurred with the agents tested; clonidine was the most potent agonist while methoxamine had no effect. The relative order of potency of the various agonists was: clonidine > adrenaline > phenylephrine > methoxamine; this order is consistent with the classification of agonists described for the presynaptic alpha 2-receptor. Moreover, selected antagonists were used in order to antagonise clonidine inhibition of theophylline-induced lipolysis. The order of potency of the alpha-antagonists for the human alpha-adrenoceptor of adipocytes was: yohimbine > piperoxane > phenoxybenzamine > prazosin. This order is consistent with an alpha 2 type receptor. In conclusion, the results demonstrate that the alpha-adrenergic receptor which inhibits lypolysis in human fat cells is of the alpha 2 type. it is noteworthy that although localized postsynaptically this alpha-receptor can be classified as alpha 2 like the commonly known presynaptic alpha-adrenergic receptor which inhibits noradrenaline release from sympathetic neurons.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6105967     DOI: 10.1016/0014-2999(80)90298-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Evidence of functional alpha 2-adrenergic receptors in adult-rat adipocytes by using the agonist UK 14304.

Authors:  M C Rebourcet; C Carpéné; M Lavau
Journal:  Biochem J       Date:  1988-06-15       Impact factor: 3.857

2.  Functional evidence that alpha 2A-adrenoceptors are responsible for antilipolysis in human abdominal fat cells.

Authors:  G Tarkovács; C Blandizzi; E S Vizi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

3.  Lipolytic response of adipocytes to epinephrine in sedentary and exercise-trained subjects: sex-related differences.

Authors:  F Crampes; D Riviere; M Beauville; M Marceron; M Garrigues
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

4.  Role of alpha 1- and alpha 2-adrenoceptors in catecholamine-induced hyperglycaemia, lipolysis and insulin secretion in conscious fasted rabbits.

Authors:  J Moratinos; C Carpene; I de Pablos; M Reverte
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

5.  [3H]-idazoxan binds with high affinity to two sites on hamster adipocytes: an alpha 2-adrenoceptor and a non-adrenoceptor site.

Authors:  A C MacKinnon; C M Brown; M Spedding; A T Kilpatrick
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

6.  Inhibitory alpha 2-adrenergic mechanism regulating gastric secretion in pylorus-ligated rats.

Authors:  T Nakadate; T Nakaki; T Muraki; R Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-08       Impact factor: 3.000

7.  Haemodynamic changes and oxygen uptake during crossclamping of the thoracic aorta in dexmedetomidine pretreated dogs.

Authors:  S Gregoretti; T Henderson; D A Parks; S Gelman
Journal:  Can J Anaesth       Date:  1992-09       Impact factor: 5.063

8.  Pharmacological characterizations of adrenergic receptors in human adipocytes.

Authors:  T W Burns; P E Langley; B E Terry; D B Bylund; B B Hoffman; M D Tharp; R J Lefkowitz; J A García-Saínz; J N Fain
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

Review 9.  [Antihypertensive therapy and lipid metabolism].

Authors:  W Krone; D Müller-Wieland; H Greten
Journal:  Klin Wochenschr       Date:  1984-03-01

10.  Different characteristics of postjunctional alpha-adrenoceptors on arterial and venous smooth muscle.

Authors:  J P Hieble; D F Woodward
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.